AlphaQuest LLC Has $1.57 Million Holdings in Chemed Corporation $CHE

AlphaQuest LLC raised its position in Chemed Corporation (NYSE:CHE) by 76.8% in the second quarter, HoldingsChannel reports. The fund owned 3,226 shares of the company’s stock after purchasing an additional 1,401 shares during the quarter. AlphaQuest LLC’s holdings in Chemed were worth $1,571,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of CHE. Alpine Bank Wealth Management bought a new position in shares of Chemed in the first quarter valued at approximately $29,000. HM Payson & Co. bought a new position in shares of Chemed in the first quarter valued at approximately $30,000. SVB Wealth LLC bought a new position in shares of Chemed in the first quarter valued at approximately $30,000. WPG Advisers LLC bought a new position in shares of Chemed in the first quarter valued at approximately $32,000. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after purchasing an additional 76 shares in the last quarter. Institutional investors own 95.85% of the company’s stock.

Insider Buying and Selling

In other news, CEO Kevin J. Mcnamara sold 3,000 shares of Chemed stock in a transaction on Friday, September 26th. The stock was sold at an average price of $461.28, for a total value of $1,383,840.00. Following the completion of the transaction, the chief executive officer directly owned 96,197 shares in the company, valued at approximately $44,373,752.16. The trade was a 3.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nicholas Michael Westfall sold 10,012 shares of Chemed stock in a transaction on Monday, August 4th. The shares were sold at an average price of $421.91, for a total value of $4,224,162.92. The disclosure for this sale can be found here. Insiders have sold a total of 13,162 shares of company stock valued at $5,677,511 in the last ninety days. 3.29% of the stock is owned by company insiders.

Chemed Price Performance

NYSE:CHE opened at $435.80 on Friday. The business has a fifty day simple moving average of $448.51 and a two-hundred day simple moving average of $499.03. Chemed Corporation has a 1 year low of $408.42 and a 1 year high of $623.60. The company has a market capitalization of $6.35 billion, a P/E ratio of 22.41, a P/E/G ratio of 2.52 and a beta of 0.43.

Chemed (NYSE:CHE) last released its earnings results on Tuesday, July 29th. The company reported $4.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.02 by ($1.75). Chemed had a return on equity of 25.83% and a net margin of 11.56%.The firm had revenue of $618.80 million during the quarter, compared to analysts’ expectations of $650.60 million. During the same period in the prior year, the business earned $5.47 earnings per share. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, analysts anticipate that Chemed Corporation will post 21.43 earnings per share for the current year.

Chemed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, August 29th. Stockholders of record on Monday, August 11th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. This is a boost from Chemed’s previous quarterly dividend of $0.50. The ex-dividend date was Monday, August 11th. Chemed’s dividend payout ratio (DPR) is presently 12.34%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CHE. Jefferies Financial Group upgraded Chemed from a “hold” rating to a “buy” rating and raised their target price for the company from $490.00 to $550.00 in a report on Tuesday, September 2nd. Bank of America dropped their price target on Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a report on Wednesday, September 10th. Royal Bank Of Canada dropped their price target on Chemed from $640.00 to $589.00 and set an “outperform” rating on the stock in a report on Thursday, July 31st. Wall Street Zen lowered Chemed from a “buy” rating to a “hold” rating in a report on Saturday, July 5th. Finally, Oppenheimer dropped their price target on Chemed from $650.00 to $580.00 and set an “outperform” rating on the stock in a report on Thursday, July 31st. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $578.50.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.